Deep Healing: Two alumni are making waves in drug discovery by plumbing the oceans’ depths for new therapeutic molecules
Sep. 6, 2018—Sirenas, a San Diego-based company founded by Vanderbilt alumni Eduardo Esquenazi, BS'98, and Jake Beverage, BA'98, is applying trailblazing methods toward drug discovery.
May. 10, 2018—The Office of the Vice Provost for Research and the Center for Technology Transfer and Commercialization have posted informational slides for faculty preparing pre-proposal submissions in response to the inaugural Ancora request for proposals.
May. 1, 2018—Vanderbilt scientists have developed a new process that can rapidly and inexpensively identify personalized cancer drugs derived from nature.
Apr. 5, 2018—Officials with Vanderbilt University Medical Center announced the creation of a wholly owned subsidiary, Nashville Biosciences, to harness the power of its extensive genomic and bioinformatics resources to advance drug and diagnostics discovery and development.
Boehringer Ingelheim and Vanderbilt University expand partnership to develop novel treatment approaches for cancer
Mar. 14, 2018—New agreement will pursue therapies targeting MCL1 (myeloid cell leukemia 1), which is highly prevalent in many difficult-to-treat cancers.
Feb. 15, 2018—The lasting impact of the historic partnership between the federal government and America's research universities is the topic of this week's column from Chancellor Nicholas S. Zeppos.
Jan. 8, 2018—Under the terms of the licensing agreement, Lundbeck has exclusively licensed rights to compounds developed at Vanderbilt that act on a receptor in the brain that has been implicated in schizophrenia.
Sep. 20, 2017—An interdisciplinary team of Vanderbilt University researchers has received a two-year, $2-million federal grant to develop an “organ-on-chip” model for two genetic forms of epilepsy.
Sep. 11, 2017—Vanderbilt University Medical Center (VUMC) and Bayer have agreed on a five-year strategic research alliance to evaluate new drug candidates for the treatment of kidney diseases, with the goal of accelerating the translation of innovative approaches from the laboratory to pre-clinical development.
Aug. 7, 2017—Developed at Vanderbilt, VU319 is designed to precisely target a specific neuron receptor associated with cognitive function while avoiding potentially dangerous side effects.
May. 25, 2017—Vanderbilt University Medical Center (VUMC), Vanderbilt University and Japan-based Ono Pharmaceutical Co. Ltd. have expanded a drug discovery agreement initiated in 2015 that will now run through 2019.
Apr. 14, 2017—Geneticists have developed an effective new method for identifying the genes that produce the chemicals plants use to protect themselves from predators, which are an important natural drug source.